These innovative treatments , including Semaglutide , belong to a group of drugs called GLP-1 agents. Originally developed for managing high blood sugar, they operate by helping the pancreas to release adequate the hormone insulin and limiting excessive glucose levels. Beyond diabetes, their ability to support weight management has contributed to s